Formulation Development and Evaluation of Risperidone CR Tablets

To achieve patients’ needs and help them tolerate the treatment best, risperidone must be administrated in a controlled fashion, allowing patients to maintain steady plasma concentrations. This research focused on formulation and optimization of controlled release (CR) supramolecular (hydrophilic swellable) matrix systems of risperidone, consisting of HPMC K15 and Polyox WSR-1105 to prolong and make convenient the dosing of the drug. A multi-factorial design of experiments was employed to systematically formulate the study where levels of HPMC K15, Polyox WSR-1105 and a filler were changed to study the overall impact of the three on matrix stability, tablet compression to hardness, and the drug release profile for 24 hours. No significant interactions were observed with the excipients and polymers selected, and the stability of the drug was confirmed with pre-formulation studies with DSC and FTIR techniques. Pharmpacopeial criteria for hardness, friability, thickness, mass variation, and drug assays were met confirming good manufacturability for the tablets. From the 12 formulations, the best formulation exhibited 24-hour release of 91.4%, confirming adequate respirable plasma profile to allow for once daily dosing. From the Kinetic analysis, the release was almost constant, indicating the drug was being released hyperbola with the volume of drug left in system.Further consideration with respect to the Korsmeyer-Peppas modeling classified the release mechanism as super diffusion case-II transport (n > 0.89). This indicates many more factors influence the release behavior than mere diffusion. Specifically, the swelling, relaxing, and progressive expansion of the polymer matrix takes over the diffusion release behavior. Also, the addition of Polyox WSR-1105, high molecular weight poly (ethylene oxide), increases gel strength and matrix hydration, thereby improving controlled release characteristics of the matrix system. Strong matrix integrity and performance to the optimum response of the composite system with HPMC K15 and Polyox WSR-1105 were characterized with the empirical behavior with the matrix tablet-controlled release of risperidone as once daily use. Lastly, the in vivo pharmacokinetic behavior also validated the release system. It demonstrated a significant change in absorption profile with a marked increase in time to reach maximum plasma concentration (Tmax 4.0 h) and a decrease in maximum plasma concentration (Cmax, 60.0 ± 9.6 ng/mL) and a significant decrease in absorption profile (comparing to the reference with immediate release, 1 time to 0.0 h and 100.0 ± 11.8 ng/mL).Despite the moderated peak, overall systemic exposure increased, as reflected by higher AUC₀–t (607.0 ± 72.5 ng·h/mL) and AUC₀–∞ (625.7 ± 78.2 ng·h/mL). An approximate transfer station time increased around two collections/units (8.16 hours, range) owing to lengthened absorptions, though the variable troth elimination levels did not change (mean elimination t_{1/2} ≈ 4.3\ hours). The study showcases the impact of design-focused formulation optimization on creating a balance to ensure a stable therapeutic with possible improved compliance on a patient-centred system with controlled and reduced adverse extensive peaks released.